Oral therapy of type 2 diabetes
DOI:
https://doi.org/10.32385/rpmgf.v21i6.10187Abstract
Type 2 diabetes is a syndrome characterized by chronic elevation of blood glucose associated with varying degrees of insulin resistance, observed since the early stages of glucose intolerance. The selection of drug therapy must be based after the initiation of non-pharmacological treatment with diet and exercise appropriate in the clinical characteristics of the person with diabetes, taking into account both the action and the risk profile of each drug, both the type and degree of changes in glycemia. The drugs available can be grouped according to their main form of action groups acting largely complementary, so that after a few years of development of diabetes will require your combination therapy. The current goal is to maintain during most of evolution a quasi normal-glucose by treating the underlying causes of their change and saving as much as possible the beta cell function.Downloads
Downloads
Published
Issue
Section
License
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
